Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone
Drug and Alcohol Dependence Reports · 2023-03 · 6 · 100138
DOI: 10.1016/j.dadr.2023.100138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Alcohol Dependence Reports, 2023-03. Verfasst von Alexis Carl und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Social Work, Wayne State University, 5447 Woodward Ave, Detroit, MI 48202, USA. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Michigan Department of Health and Human Services, Wayne State University, Substance Abuse and Mental Health Services Administration.
Abstract (Originalsprache)
Background
Medications for Opioid Use Disorder (MOUD) are efficacious, however only one-third of individuals with an opioid use disorder (OUD) enter into treatment. Low rates of MOUD utilization are partially due to stigma. This study examines provider-based stigma toward MOUD and identifies factors associated with experiencing stigma related to MOUD from substance use treatment and healthcare providers among people receiving methadone.
Methods
Clients receiving MOUD at an opioid treatment program (N = 247) were recruited to complete a cross-sectional computer-based survey assessing socio-demographics, substance use, depression and anxiety symptoms, self-stigma, and recovery supports/barriers. Logistic regression was used to examine factors associated with hearing negative comments about MOUD from substance use treatment and healthcare providers.
Results
27.9% and 56.7% of respondents reported they sometimes/often hear negative comments about MOUD from substance use treatment and healthcare providers, respectively. Logistic regression results indicate that individuals who experience more negative consequences resulting from their OUD (OR=1.09, p=.019) had greater odds of hearing negative comments from substance use treatment providers. Age (OR=0.966, p=.017) and treatment stigma (OR=1.42, p=.030) were associated with greater odds of hearing negative comments from healthcare providers.
Conclusions
Stigma can be a deterrent to seeking substance use treatment, healthcare, and recovery support. Understanding factors associated with experiencing stigma from substance use treatment providers and healthcare providers is important as these individuals may act as advocates for those with OUD. This study highlights individual factors associated with hearing negative comments about methadone and other MOUD and point to areas for targeted education.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Social Work, Wayne State University, 5447 Woodward Ave, Detroit, MI 48202, USA.
- School of Social Work, Rutgers University - New Brunswick, 120 Albany Street, Tower One, New Brunswick, NJ 08901, USA.
- Merrill Palmer Skillman Institute, Wayne State University, 71 E Ferry St, Detroit, MI 48202, USA.
Förderung
- Michigan Department of Health and Human Services
- Wayne State University
- Substance Abuse and Mental Health Services Administration
Zitieren
APA
Carl, A., Pasman, E., Broman, M. J., Lister, J. J., Agius, E., & Resko, S. M. (2023). Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug and Alcohol Dependence Reports, 6, 100138. https://doi.org/10.1016/j.dadr.2023.100138
Vancouver
Carl A, Pasman E, Broman MJ, Lister JJ, Agius E, Resko SM. Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone. Drug and Alcohol Dependence Reports. 2023;6:100138. doi:10.1016/j.dadr.2023.100138
BibTeX
@article{Carl2023,
author = {Carl, Alexis and Pasman, Emily and Broman, Michael J and Lister, Jamey J and Agius, Elizabeth and Resko, Stella M},
title = {Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone},
journal = {Drug and Alcohol Dependence Reports},
year = {2023},
volume = {6},
pages = {100138},
doi = {10.1016/j.dadr.2023.100138}
}
EUVIMED